Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.6252W HIGH $21.34
Volume
5.12 K
Value Traded
705.78 K
Short % Float
-
-2.8%Week
-15.39%1 Month
-32.71%3 Month
-40.74%6 Month
+4.83%5 Year
-21.35%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
688.67 M
EPS (TTM)
0.18
P/E Ratio
54.69
Ent. Value
861.23 M
Total Shares
70.78 M
Float Shares
-
Insiders
-
Institutions
1.33%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PHAR Catalyst Timeline
Dated clinical, regulatory and corporate events for Pharming Group N.V.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pharming Group N.V.
374Total events
23Upcoming
90Tier-1 (high impact)
2004 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲FDA Filing AcceptedJoenja®ApprovedRegulatory Filing
FDA accepts sNDA for lower doses of Joenja in children with APDS
activated phosphoinositide 3-kinase delta syndrome (APDS) in children aged 4 years and older weighing between 13 kg and 27 kgsource ↗
▲Priority ReviewJoenja®ApprovedRegulatory Filing
FDA grants Priority Review to sNDA for lower doses of Joenja
activated phosphoinositide 3-kinase delta syndrome (APDS) in children aged 4 years and older weighing between 13 kg and 27 kgsource ↗
▲Topline ReadoutLeniolisibApprovedClinical Data
Positive Phase II topline data for leniolisib in PIDs with immune dysregulation
genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kd signalingsource ↗
▲Supplemental ApprovalJoenja®ApprovedFDA Decision
FDA approves supplemental NDA for Joenja (leniolisib) 40 mg and 50 mg BID in children with APDS ages 4 to 11
activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in children aged 4 to 11 years weighing at least 27 kgsource ↗
▲Label ExpansionJoenja®ApprovedFDA Decision
FDA expanded approval of Joenja to children aged 4 to 11 years weighing at least 27 kg
activated phosphoinositide 3-kinase delta syndrome (APDS) in children aged 4 to 11 years weighing at least 27 kgsource ↗
▲Product LaunchJoenja®ApprovedPost-Market
Commercial launch of Joenja in Japan for APDS patients aged 4 and older
activated PI3K delta syndrome (APDS)source ↗
●Timing GuidanceJoenja®ApprovedPresentation
Planned sNDA submission for lower doses in patients weighing 13-27 kg
APDS in patients weighing 13-27 kgsource ↗
▲Enrollment CompleteLeniolisibApprovedTrial
Patient enrollment complete in two Phase II trials of leniolisib for PIDs
Primary immunodeficiencies (PIDs) including CVIDsource ↗
●sNDA SubmissionJoenja®ApprovedRegulatory Filing
Pharming submits separate sNDA for lower Joenja doses in pediatric APDS patients weighing 13 kg to <27 kg
pediatric APDS patients aged 4 to 11 years who weigh 13 kg to less than 27 kgsource ↗
▲Other Regulator MilestoneJoenja®ApprovedEx-US Regulatory
Joenja approved by South Korea MFDS
APDS in adult and pediatric patients 12 years and oldersource ↗
▲FDA ApprovalJoenja®ApprovedFDA Decision
Joenja approved by South Korea MFDS
APDS in adult and pediatric patients 12 years and oldersource ↗
▲Other Regulator MilestoneJoenja®ApprovedEx-US Regulatory
Joenja approved by Health Canada
APDS in adult and pediatric patients 12 years and oldersource ↗
▲FDA ApprovalJoenja®ApprovedFDA Decision
Joenja approved by Health Canada
APDS in adult and pediatric patients 12 years and oldersource ↗
●Timing GuidanceJoenja®ApprovedPresentation
Plan to submit separate sNDA for lower doses in patients 13-27 kg
APDS in patients weighing 13-27 kgsource ↗
◆Oral PresentationPresentation
Pharming CEO participates in Fireside Chat at Jefferies Global Healthcare Conference
▲FDA Filing AcceptedJoenja®ApprovedRegulatory Filing
FDA accepted resubmitted sNDA for Joenja in pediatric APDS
APDS in children aged 4 to 11 yearssource ↗
▲EU ApprovalJoenja®ApprovedEx-US Regulatory
European Commission granted Marketing Authorization for Joenja
APDS in adult and pediatric patients 12 years and oldersource ↗
◆Poster PresentationLeniolisibApprovedPresentation
Phase 2 Clinical Study of Leniolisib in Primary Immunodeficiencies with Enhanced PI3K Pathway Signaling: Study Design & Subject Baseline Characteristics
Primary Immunodeficiencies with Enhanced PI3K Pathway Signalingsource ↗
◆Poster PresentationPresentation
Caregivers of Children with APDS Balance Complex Medical Care, Family, and Work Responsibilities
APDSsource ↗
◆Poster PresentationLeniolisibApprovedPresentation
Clinical Experience with Use of Leniolisib to Treat Immune Dysregulation in Patients with CVID and CVID-Like Disorders
CVID and CVID-like disorderssource ↗
◆Poster PresentationPresentation
Pediatric and Adolescent APDS: Demographic and Clinical Findings from the APDS-CHOIR Registry
APDSsource ↗
●NDA SubmissionJoenja®ApprovedRegulatory Filing
Resubmitted pediatric sNDA for 40 mg and 50 mg doses
APDSsource ↗
▲Enrollment CompleteLeniolisibApprovedTrial
Enrollment completed in two Phase II trials for leniolisib in PIDs
primary immunodeficiencies with immune dysregulationsource ↗
●Oral PresentationLeniolisibApprovedPresentation
Presentation at CIS Annual Meeting on leniolisib compassionate use in CVID
CVID and CVID-like disorderssource ↗
▲Oral PresentationLeniolisibApprovedPresentation
Presentation at CIS 2026 on leniolisib expanded access in CVID
CVID and CVID-like disorderssource ↗
◆Oral PresentationPresentation
Van Lanschot Kempen Life Sciences Conference 2026 participation
◆Oral PresentationPresentation
25th Annual Needham Virtual Healthcare Conference presentation
◆EU ApprovalJoenja®ApprovedEx-US Regulatory
Expected European Commission decision on Joenja marketing authorization
activated phosphoinositide 3-kinase delta syndrome (APDS)source ↗
◆Topline ReadoutLeniolisibApprovedClinical Data
Topline results from Phase 2 trials of leniolisib in CVID and PIDs with immune dysregulation
CVID and PIDs with immune dysregulation beyond APDSsource ↗
◆PMDA MilestoneLeniolisibApprovedEx-US Regulatory
PMDA decision on leniolisib NDA expected by end of March 2026
APDS in adult and pediatric patients 4 years and oldersource ↗
▲CHMP Positive OpinionJoenja®ApprovedEx-US Regulatory
CHMP positive opinion for Joenja for APDS in patients 12 years and older
activated phosphoinositide 3-kinase delta syndrome (APDS)source ↗
●Type A MeetingJoenja®ApprovedFDA Meeting
Type A meeting with FDA on March 26, 2026
APDS in children aged 4 to 11 yearssource ↗
▲CHMP Positive OpinionJoenja®ApprovedEx-US Regulatory
CHMP positive opinion for Joenja in EU for patients 12+
APDSsource ↗
▲PMDA MilestoneJoenja®ApprovedEx-US Regulatory
MHLW approval of Joenja for APDS in patients aged 4 years and older
activated PI3K delta syndrome (APDS)source ↗
▲Enrollment CompleteLeniolisibApprovedTrial
Enrollment completed in two Phase II trials of leniolisib for PIDs
Additional primary immunodeficiencies (PIDs) with immune dysregulationsource ↗
▲Other Regulator MilestoneJoenja®ApprovedEx-US Regulatory
Joenja approved in Japan for patients 4+
APDSsource ↗
◆Type A MeetingJoenja®ApprovedFDA Meeting
Type A meeting with FDA expected in March 2026 to discuss CRL
APDS in children aged 4 to 11 yearssource ↗
◆PMDA MilestoneLeniolisibApprovedEx-US Regulatory
PMDA decision expected for leniolisib in Japan
APDSsource ↗
▲FDA ApprovalJoenja®ApprovedFDA Decision
MHLW approval of Joenja in Japan for APDS
activated PI3K delta syndrome (APDS)source ↗
◆Oral PresentationPresentation
Pharming to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Past FDA Catalysts and PDUFA Decisions
How PHAR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-11 | Joenja (leniolisib) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C44 / 100
Pipeline Score
$217M
Pipeline Value
$873M
Commercial Value
Undervalued
Valuation Signal
3
Drugs Scored
1.1x
rNPV / MCap
Top 30%
Micro Cap(rank 198 of 658)
Percentile Rank
Pharming Group N.V. carries a moderate pipeline score (44/100), with $661M risk-adjusted pipeline value, led by rhC1INH in Hereditary Angioedema (Phase 3).
Commercial products (revenue basis: latest annual revenue in its 20-F, to Dec 2025; product lines from the latest annual filing) Revenue $376.1M x 2.3 = $873M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| RUCONEST | $318M | $252M | +26% |
| JOENJA | $58M | $45M | +29.4% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| rhC1INH Small moleculeCompletedNCT01359969 | Hereditary Angioedema | Phase 3 | COMPLETED | 132 | Jul 17, 2017 |
Clinical Trial Results
Readouts, endpoints and source filings for every PHAR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| leniolisib PriorityOrphan | primary immunodeficiencies (PIDs) with immune dysregulation | Phase 2 | 2026-09-22 | mean spleen volume reduction: 26.4%Read More | Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PHAR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PHAR for Q2 2026. | ||||
PHAR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PHAR ranks across every disease it competes in
Competitive Position is a premium feature
See how PHAR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPHAR News
PHARPharming announces CEO transition
Pharming has announced a leadership transition as CEO Fabrice Chouraqui steps down. The Board of Directors appointed Leverne Marsh and Kenneth Lynard as Interim Co-CEOs to ensure continuity. The decision follows a mutual agreement on differing views regarding the company's strategic direction. Pharming's commitment to its patients and strategic priorities remains intact.
Read more →PHARPharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
Pharming announced that the FDA has accepted its supplemental New Drug Application for lower doses of Joenja, aimed at treating children aged 4 years and older with activated phosphoinositide 3-kinase delta syndrome (APDS). The application has been granted Priority Review, with a target action date set for January 30, 2027. This follows the recent approval of Joenja for older children weighing at least 27 kg, expanding access to younger patients.
Read more →PHARPharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
Pharming announced positive topline data from its Phase II trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation. The results, accepted as a late-breaking abstract for ESID 2026, highlighted significant clinical improvements, including a mean 26.4% reduction in spleen volume. The drug was well-tolerated, with no new safety signals reported. Pharming plans to present additional data at the conference and expects to report results for leniolisib in common variable immunodeficiency (CVID) later this year.
Read more →PHARFDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
Pharming's Joenja (leniolisib) has received FDA approval for use in children aged 4 to 11 with activated phosphoinositide 3-kinase delta syndrome (APDS). This marks the first FDA-approved treatment for this age group in the U.S. The new dosing options will be available in October, providing a critical intervention for managing APDS symptoms and improving children's health outcomes.
Read more →PHARPharming Group to participate in September investor conferences
Pharming Group N.V. announced its participation in two investor conferences in September 2026. CEO Fabrice Chouraqui will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, followed by participation in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. The company encourages scheduling one-on-one meetings with its management team.
Read more →PHARPharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
Pharming Group has launched Joenja (leniolisib) in Japan for patients aged 4 and older with activated PI3K delta syndrome (APDS). This marks the first commercial availability of Joenja for children aged 4 to 11 globally. The launch follows its approval by Japan's Ministry of Health and highlights Pharming's commitment to rare disease treatment.
Read more →PHARPharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
Pharming Group N.V. will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan, VP of Investor Relations, will lead a Fireside Chat Q&A session on August 12. The company invites interested parties to schedule meetings with its management team during the conference.
Read more →PHAR▼ -10.5%on this newsshared move
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
Pharming Group N.V. reported a 3% decrease in total revenues for Q2 2026, totaling $90.2 million. While RUCONEST revenue fell by 10%, Joenja saw a significant 40% increase. The company revised its revenue guidance downward but remains optimistic about the growth potential of Joenja and upcoming clinical data readouts. Pharming is also focusing on operational efficiency and expanding its rare disease portfolio.
Read more →PHARPharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
Pharming Group N.V. will report its preliminary financial results for the second quarter and first half of 2026 on July 30, 2026. The company will also provide a business update during a conference call and webcast scheduled for the same day. Interested participants must register in advance to access the call.
Read more →PHARPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Pharming Group announced the FDA's acceptance of its resubmitted supplemental New Drug Application for Joenja (leniolisib) to treat children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). If approved, Joenja will be the first treatment for this rare immunodeficiency in the U.S. The resubmission includes additional data requested by the FDA and has a target action date of October 24, 2026.
Read more →PHAR▼ -6.3%on this newsshared move
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York
Pharming Group announced its participation in the 2026 Jefferies Global Healthcare Conference in New York, scheduled for June 3-4, 2026. CEO Fabrice Chouraqui will take part in a Fireside Chat Q&A session on June 4 at 11:05am EDT. The event will be accessible via a live webcast and replay on Pharming's website.
Read more →PHARPharming Group announces results of 2026 Annual General Meeting of Shareholders
Pharming Group held its Annual General Meeting of Shareholders on May 28, 2026, where all proposed agenda items were approved. Key decisions included the appointment of KPMG as the independent auditor for 2026-2028 and amendments to the remuneration policy for Non-Executive Directors. Shareholders also renewed authorizations for share issuance and repurchase.
Read more →PHAREuropean Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union
The European Commission has granted marketing authorization for Joenja® (leniolisib), marking it as the first approved treatment for activated PI3K delta syndrome (APDS) in the EU. The drug is expected to launch in Germany in Q3 2026. This approval follows previous approvals in several countries, reinforcing Pharming's commitment to addressing rare diseases.
Read more →PHAR▼ -26.8%on this news
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
Pharming Group N.V. announced its participation in the 2026 Annual Meeting of the Clinical Immunology Society, where it will present interim outcomes from a long-term study of leniolisib in pediatric patients with activated PI3Kδ syndrome (APDS). The presentations will also cover clinical data from leniolisib's use in treating immune dysregulation in patients with Common Variable Immunodeficiency (CVID) and related disorders. Two phase II trials are currently evaluating leniolisib's safety and tolerability in these patient populations.
Read more →PHAR▼ -26.8%on this newsshared move
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
Pharming Group reported its Q1 2026 financial results, revealing total revenues of $72.4 million, an 8% decrease from the previous year. Notably, Joenja® saw a 34% revenue increase, driven by strong uptake in the U.S. and international markets. The company reaffirmed its revenue guidance for 2026 and made significant regulatory progress, including approvals in Japan and a positive opinion from the CHMP in Europe.
Read more →PHARPharming Group to report first quarter 2026 financial results and provide business update on May 7
Pharming Group N.V. has announced that it will report its preliminary financial results for the first quarter of 2026 and provide a business update on May 7, 2026. Management will host a conference call and webcast for analysts and investors at 13:30 CEST/07:30 am EDT on the same day. Interested participants can register in advance for both the conference call and the webcast. Following the event, a replay will be available on the Pharming website.
Read more →PHARPharming Group announces the 2026 Annual General Meeting of Shareholders
Pharming Group N.V. has scheduled its 2026 Annual General Meeting of Shareholders for May 28, 2026. The agenda includes appointing KPMG N.V. as the external auditor and proposals to amend the remuneration policy for Non-Executive Directors. Additionally, the Board will seek renewal of share issuance and repurchase authorizations. The meeting will be held at the Corpus Congress Centre and will be webcast live.
Read more →PHARPharming Group N.V. Investigated by the Portnoy Law Firm
Pharming Group N.V. is currently facing an investigation by the Portnoy Law Firm due to potential securities fraud. This follows a dramatic decline in the company's stock price after the FDA's issuance of a Complete Response Letter concerning the supplemental New Drug Application for Joenja® (leniolisib). The FDA highlighted significant issues regarding pediatric dosing and manufacturing practices, prompting investor concern and legal scrutiny. As the firm prepares to possibly file a class action on behalf of investors, it emphasizes the seriousness of the company's regulatory challenges.
Read more →PHARPharming Group to participate in April investor conferences
Pharming Group N.V. has announced its participation in two investor conferences in April 2026. The CEO and CMO will present at the Needham Virtual Healthcare Conference on April 13, followed by attendance at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 15. This engagement aims to strengthen investor relations and showcase Pharming's innovative portfolio.
Read more →PHARPharming Group announces the filing of its 2025 Annual Report and Form 20-F
Pharming Group N.V. has announced the filing of its Annual Report for the year ending December 31, 2025, which is now available online. Additionally, the company has filed its Annual Report on Form 20-F with the U.S. SEC. Pharming is committed to developing innovative treatments for patients with rare diseases.
Read more →About Pharming Group N.V.
BIOPHARMAWATCH ELITE PLUS
Trade the next PHAR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime